Recent News for TGTX - TG Therapeutics, Inc.

Date Title
Jun 27 Is TG Therapeutics, Inc.'s (NASDAQ:TGTX) Balance Sheet Strong Enough To Weather A Storm?
Jun 27 TG Therapeutics: Hitting A Growth Inflection
Jun 18 TG Therapeutics to Present at the Raymond James Life Sciences and MedTech Conference
Jun 17 TG Therapeutics Presents Preclinical Data for TG-1801, a First-in-Class Anti-CD47/CD19 Bispecific Antibody, at the 24th European Hematology Association Annual Congress
Jun 11 TG on go with U.S. application for umbralisib in MZL
Jun 11 TG Therapeutics Confirms Registration Path for Umbralisib in Marginal Zone Lymphoma Following FDA Meeting
Jun 5 TG up 4% on positive umbralisib data in MZL
Jun 4 TG Therapeutics Presents Positive Interim Data from UNITY-NHL Phase 2b Trial Evaluating Umbralisib Monotherapy in Patients with Marginal Zone Lymphoma at the 55th American Society of Clinical Oncology (ASCO) Annual Meeting
Jun 4 TG Therapeutics to Present at the Jefferies 2019 Healthcare Conference
Jun 1 The Week Ahead In Biotech: ASCO Presentations Pick Up The Pace
May 28 TG Therapeutics May Have Potential but the Charts Need More Work
May 23 TG Therapeutics CEO: Going through the process to reach big markets
May 16 TG Therapeutics Announces Data Presentations at Upcoming Medical Meetings
May 14 TG Therapeutics: Varied Pipeline With 2 Lead Candidates In Late Stage, Low Cash Position
May 11 Edited Transcript of TGTX earnings conference call or presentation 10-May-19 12:00pm GMT
May 10 TG Therapeutics, Inc. (TGTX) CEO Michael Weiss on Q1 2019 Results - Earnings Call Transcript
May 10 Merck KGaA's evobrutinib shows durable effect in mid-stage MS study
May 10 TG Therapeutics Inc (TGTX) Q1 2019 Earnings Call Transcript
May 10 TG Therapeutics net loss improves in Q1
May 10 TG Therapeutics: 1Q Earnings Snapshot
May 10 TG Therapeutics EPS and revenue in-line
May 10 TG Therapeutics Provides Business Update and Reports First Quarter 2019 Financial Results
May 9 TG Therapeutics to Host Conference Call on First Quarter 2019 Financial Results and Business Update
May 7 TG Therapeutics Announces Long-term Follow-up Data from the Phase 2 Trial of Ublituximab in Patients with Multiple Sclerosis at the American Academy of Neurology 71st Annual Meeting
Apr 26 Key events - healthcare (Part 2)
Back to the Main TGTX Page...